Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices
NCT ID: NCT07268937
Last Updated: 2025-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2023-07-06
2025-05-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Methods for the quantitative and non-invasive assessment of liver fat content have recently been implemented on ultrasound devices, based on the estimation of the ultrasound beam attenuation coefficient and backscattering. These methods are CE marked and already commercially available.
The aim of the study is to compare the results of the degree of steatosis detected by different ultrasound devices with the degree of steatosis of the CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
NCT05120557
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
NCT04782050
Ultrasound and Attenuation Imaging
NCT06552377
Sonoelastography: Ultrasound Method to Measure Liver Fibrosis
NCT01747772
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
NCT06661655
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAP (Controlled Attenuation Parameter) module implemented on the Fibroscan machine.
Use of the CAP module implemented on the Fibroscan machine to compare the results of the degree of steatosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ability to hold breath for image acquisition,
* informed consent
Exclusion Criteria
* any condition which, in the clinical judgement of the investigator, will make further participation in the study unacceptable for that individual patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione IRCCS Policlinico San Matteo di Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gianluigi Poma
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fondazione IRCCS Policlinico San Matteo, SSD Malattie Infettive 3 - Ecografia
Pavia, Pavia, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
p_168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.